Arcus Biosciences, Inc. Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Arcus Biosciences, Inc. (RCUS) had Deferred Tax Assets, Operating Loss Carryforwards, State and Local of $39.00 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $39.00M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $5.00M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $1.00M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $24.00M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | Deferred Tax Assets, Operating Loss Carryforwards, State and Local as first filed |
|---|---|---|
| 2025-12-31 | $39.00M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $5.00M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $1.00M 10-K · filed 2025-02-25 | |
| 2022-12-31 | $24.00M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $24.00M 10-K · filed 2023-02-28 | $24.18M 10-K · filed 2022-02-23 |
| 2020-12-31 | $54.53M 10-K · filed 2022-02-23 | |
| 2019-12-31 | $30.05M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $16.08M 10-K · filed 2020-03-05 | |
| 2017-12-31 | $11.10M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |